Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 15/20 | 0.75 |
| ▸ | CCR2 | P41597 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27486 | 0.89 | LMNA (0.72) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL343149 | 0.89 | CCR9 (0.78) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL27433 | 0.87 | CCR9 (0.74) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL343179 | 0.85 | CCR9 (1.00) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL10248530 | 0.84 | CCR9 (0.77) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL28412 | 0.84 | CCR9 (0.69) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL12032397 | 0.83 | CCR9 (0.70) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL27420 | 0.83 | CCR9 (0.68) | CCR9LMNAHTTTP53MAPT | |
| SCHEMBL344257 | 0.83 | CCR9 (0.75) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL343133 | 0.83 | CCR9 (1.00) | CCR9CCR2LMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107735401-B | Substituted dihydropyrrolopyrazole derivatives | 宇部兴产株式会社 | 2021-08-31 | — | — | CN | claimed |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2019-04-30 | — | — | US | claimed |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| US-8815887-B2 | Prophylactic or therapeutic method for Sjogren's syndrome | MILLENIUM PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | claimed |
| EP-1798223-B2 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2014088113-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME USING SPECIFIC CCR9 RECEPTOR INHIBITORS/ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | WO | claimed |
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-06-05 | — | — | US | claimed |
| EP-2402310-A1 | CCR9 inhibitors and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2399903-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| EP-1798223-B1 | Aryl sulfonamides | CHEMOCENTRYX INC (US) | 2011-07-20 | — | — | EP | claimed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| EP-3885347-B1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORP (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-3018123-B1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2023-05-10 | — | — | EP | disclosed |
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3885347-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060111351-A1 | Aryl sulfonamides | CHEMOCENTRYX, INC. | 2006-05-25 | — | — | US | disclosed |
| WO-2005112925-A1 | ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050137193-A1 | Aryl sulfonamides | CHEMOCENTREYX | 2005-06-23 | — | — | US | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002303-A1 | DIHYDROPYRROLOPYRAZOLE DERIVATIVE | CBR3, SLC13A3, CYP3A5 | CCR9 1918/4885CCR2 499/4885LMNA 3907/4885 |
| US-20050137193-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
| US-20140155437-A1 | PROPHYLACTIC OR THERAPEUTIC METHOD FOR SJOGREN'S SYNDROME | SSB, SCLY, HLA-DRB1 | CCR9 1218/4885CCR2 1700/4885LMNA 3957/4885 |
| US-20060111351-A1 | Aryl sulfonamides | CCR9, CCR1, CCR2 | CCR9 1/4885CCR2 3/4885LMNA 4484/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-10273252-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | CCR9 3773/4885CCR2 1187/4885LMNA 4373/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | CCR9 1759/4885CCR2 2460/4885LMNA 4543/4885 |
| US-20180186818-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | CCR9 3773/4885CCR2 1187/4885LMNA 4373/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.